Histrelin Shortage Update: What Patients Need to Know in 2026

Histrelin has a complicated availability story — one involving a permanently discontinued product, a still-available specialty drug, and a complex access system that leaves many patients confused. Here is everything you need to know about Histrelin availability as of 2026.

The Short Answer: Is Histrelin Available in 2026?

It depends on which form you need:

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop — but only through specialty pharmacies, with mandatory prior authorization and very high cost.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop — Endo Pharmaceuticals stopped making Vantas in September 2021 and it will not return to market.

What Happened to Vantas?

Vantas (histrelin acetate 50 mg implant for advanced prostate cancer) was manufactured alongside Supprelin LA at the same Endo Pharmaceuticals facility. In early 2021, the company began reporting that batches of Vantas were not meeting quality standards. Despite containing the same active ingredient — 50 mg histrelin acetate — the two implants were not identical products. Endo ultimately decided to discontinue Vantas entirely in September 2021.

As of 2026, Vantas has not returned to market and there is no FDA-approved generic histrelin implant for prostate cancer. Patients with advanced prostate cancer who were on Vantas have been transitioned to other androgen deprivation therapies by their oncologists or urologists.

What Is the Current Status of Supprelin LA in 2026?

Supprelin LA (histrelin for central precocious puberty in children) continues to be manufactured and distributed by Endo Pharmaceuticals as of 2026. It is not on the FDA's current drug shortage list. However, accessing it remains challenging for many families for the following reasons:

It is only available at specialty pharmacies — not retail or chain pharmacies

Prior authorization is required by virtually all insurance plans

The list price is approximately $49,000 per implant, creating affordability barriers

There is no generic version available

Is Histrelin on the FDA Drug Shortage List in 2026?

As of early 2026, Supprelin LA is not listed as an active shortage on the FDA Drug Shortages database. The Vantas shortage was resolved in a sense — by the product being permanently discontinued, not by the shortage being fixed. The ASHP (American Society of Health-System Pharmacists) drug shortage bulletin for histrelin, last updated in September 2021, notes that Vantas has been discontinued and only Supprelin LA remains available.

This means that the "shortage" situation most patients encounter with Histrelin today is not a manufacturing disruption — it is an access and distribution challenge. The drug exists; getting it is the difficult part.

38,224+ patients found their medications in stock

38K+

Find Histrelin In Stock Today →

What Should Patients Do If They're Having Trouble Getting Supprelin LA?

If you are struggling to access Supprelin LA, here is a practical action plan:

Contact the Supprelin LA Support Center at 866-316-7263 to identify which specialty pharmacies have stock.

Ask your prescribing physician to contact the specialty pharmacy directly — many practices handle this for their patients.

Apply for Endo's Patient Assistance Program if cost or insurance denial is the barrier.

Use medfinder to find specialty pharmacies near you that can fill your prescription.

If access issues cannot be resolved quickly, ask your pediatric endocrinologist about temporary alternatives (see our guide: Alternatives to Histrelin).

Looking Ahead: Will Access to Histrelin Improve?

There is no announced timeline for a generic histrelin implant. As a branded specialty drug with a complex manufacturing process (implant formulation, sterile production), generics face significant barriers to entry. For now, Supprelin LA will remain the only histrelin product available, and access will continue to depend on the specialty pharmacy network, insurance coverage, and manufacturer support programs.